Scientists at Stanford University have identified a specific brain region that appears to drive core autism symptoms in mice and successfully improved those behaviors using targeted treatments. The breakthrough focuses on overactive neurons deep in the brain that serve as gatekeepers for sensory information, controlling what signals reach conscious awareness
The findings, published in Science Advances, come from mouse studies, a standard model in autism research, and more work is needed before testing in humans. Still, the results point toward potential therapies that may address autism’s biological foundations rather than just managing symptoms.
Overactive Brain Cells Disrupt Normal Function
The problem originates in a brain structure called the reticular thalamic nucleus, which acts like a traffic control system for sensory information. In healthy brains, this region determines which sensory signals (sounds, sights, and touches) warrant attention from higher brain areas. In autism-model mice, however, these neurons fired in rapid, excessive bursts that scrambled normal brain communication.
Stanford researchers studied mice engineered to lack Cntnap2, a gene strongly linked to autism in humans. These mice exhibited classic autism-like traits, including social avoidance of other mice, repetitive grooming, hyperactivity, and increased seizure susceptibility. Brain examinations revealed that reticular thalamic nucleus neurons were firing far more frequently than normal.
Scientists traced this hyperactivity to overactive calcium channels, proteins that regulate how neurons communicate. In autism-model mice, these T-type calcium channels enabled neurons to burst-fire much more easily, resulting in disrupted brain signals that manifested as behavioral symptoms.
Two Treatment Methods Show Promise
Researchers tested whether reducing this neural overactivity could restore normal behavior using two different approaches, both of which produced remarkable results.
First, they administered Z944, a drug that blocks the problematic calcium channels, to the mice. Mice receiving this treatment showed substantial behavioral improvements, including decreased hyperactivity, restored social preferences, and cessation of excessive grooming behaviors. Z944 has already undergone human testing for treating certain seizure types, which could speed its potential path to autism trials.
The second method used advanced genetic tools called DREADDs (designer receptors exclusively activated by designer drugs). Scientists modified the mice so specific neurons could be controlled using engineered proteins and matching drugs. When they used this technique to quiet reticular thalamic nucleus activity, autism-like behaviors improved substantially again.
